Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmeridian Step Therapy Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentmeridianPolicy N/A

    2026 Step Therapy Criteria — select CNS agents (antidepressants, antipsychotics, dextromethorphan/bupropion, trazodone)

    Customize your policy alerts

    Sign up for all meridian policy alerts

    Know when meridian releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Meridian Health Plan step therapy requirements for selected antidepressants, oral antipsychotics, dextromethorphan/bupropion products (Auvelity/Exxua), and trazodone; applies to prior authorization and coverage decisions for affected pharmacy products under Meridian's 2026 policy.

    Policy Summary
    Payermeridian
    Policy2026 Step Therapy Criteria — select CNS agents
    Policy CodePolicy N/A
    Change TypeMinor — no material coverage changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain and document required prior Step drug trials (timing and products per section) or clearly document an approved exception when requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4therapeutic sections
    Step 1 & 2step levels
    180lookback days
    1min Step1 trials (some)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2min Step1 trials (antipsych)
    3trazodone tablet strengths

    Coverage Criteria — Step Therapy Rules

    Antidepressant Step Therapy

    Antidepressants — Step therapy rules

    Antidepressant Step 1 prerequisite: Coverage for Step 2/brand antidepressant products requires that at least one Step 1 drug has been tried with at least a 1-day supply in the prior 180 days.1 trial within 180 days

    Step 1 drugs include bupropion SR/XL, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine IR/ER; Exxua may be approved without prerequisites for patients with suicidal ideation or if the patient is currently taking or has previously taken Exxua.

    Oral Antipsychotic Step Therapy

    Oral antipsychotics — Step therapy rules

    Antipsychotic Step 1 prerequisite: Coverage for Step 2 oral antipsychotic products will be provided only if two distinct Step 1 oral antipsychotic drugs have been tried (each with at least a 1-day supply in the prior 180 days).2 distinct Step 1 trials within 180 days

    Step 1 drugs include oral formulations of aripiprazole, asenapine, brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, xanomeline/trospium, or ziprasidone. A brand-name equivalent trial counts. Approve Fanapt if the patient is currently taking Fanapt or has taken Fanapt in the past.

    Dextromethorphan/Bupropion Step Therapy

    Dextromethorphan/Bupropion (Auvelity/Exxua) — Step therapy rules

    Auvelity prerequisite: Coverage for Auvelity is approved if the patient has tried a generic SSRI or SNRI AND bupropion for any trial duration within the previous 180 days.SSRI or SNRI + bupropion trial within 180 days

    Exceptions: approve Auvelity without prerequisite trials for current suicidal ideation, for agitation associated with dementia due to Alzheimer's disease, or if the patient is currently taking or has previously taken Auvelity.

    Exxua exceptions: Approve Exxua without prerequisite trials if the patient has current suicidal ideation, or approve if the patient is currently taking or has previously taken Exxua.exception or documented prior/current use

    Otherwise follow Step 1 drug trial rules per the antidepressant section.

    Trazodone Step Therapy

    Trazodone — Step therapy rules

    Trazodone Step structure: Trazodone products are organized into Step 1 (generic trazodone tablets) and Step 2 (Raldesy oral solution).N/A

    Tablet strengths referenced include 50 mg, 100 mg, and 150 mg.

    Step therapy criteria for Raldesy

    Covered when ALL of the following step-based conditions are met:

    Step 1: Patient has trialed a tablet dosage form of generic trazodone (any listed tablet strength) with at least a 1-day supply in the prior 180 days.>=1-day supply in prior 180 days

    Tablet strengths referenced: 50 mg, 100 mg, 150 mg.

    Step 2 (Raldesy approval conditions): Approve Raldesy 10 mg/mL oral solution if the patient has difficulty swallowing tablets OR is currently taking Raldesy OR has taken Raldesy at any time in the past.

    Per the Auvelity step-therapy rules, coverage for Auvelity may be approved without prerequisite drug trials when the request is for agitation associated with dementia due to Alzheimer’s disease. This mirrors other listed exceptions (for example, current suicidal ideation or current/prior Auvelity use) that allow bypassing the usual SSRI/SNRI + bupropion trial requirement described for Auvelity.

    This portion of the policy does not list any additional explicit exclusions for the covered products in these sections.

    No not-medically-necessary (NMN) statements are specified in this section of the policy.

    Operational Parameters & Lookback

    Prior trial lookback — 180 days
    Lookback periodPrior 180 days
    Applies toRequired prior Step 1 or Step 2 drug trials for antidepressants, oral antipsychotics, and Auvelity/Exxua
    Evidence requiredAt least a 1-day supply of the prior drug within the 180-day lookback to count as a trial
    Minimum Step 1 trials — Antidepressants
    Minimum Step 1 trials>= 1 trial of a listed Step 1 antidepressant
    Trial duration definitionAt least a 1-day supply within the prior 180 days counts as a trial
    Exceptions

    Provider Requirements, Prior Authorization & Documentation

    Prior Authorization

    PA requires documented Step trials or an exception

    Prior authorization requires submission of evidence that the required prior Step medication trials were completed (timing and products as specified in the applicable section) or documentation of an accepted exception (for example: current suicidal ideation, current/prior use of the requested product, or agitation associated with Alzheimer’s disease).

    • Evidence must show the specific Step drug(s) tried and timing within the prior 180 days where required.
    Prior Authorization

    PA for Raldesy requires meeting step criteria or documented exception

    For Raldesy, prior authorization is granted only when step-therapy criteria are met — i.e., a prior trial of a tablet dosage form of generic trazodone (with at least a 1-day supply in the prior 180 days) — or when a documented reason to bypass the tablet trial is provided (difficulty swallowing, current or prior Raldesy use).

    • Approval also allowed if the patient is currently taking Raldesy or has taken it in the past, or cannot swallow tablets.

    Background & Policy Scope

    This policy section defines Meridian’s operational step-therapy approach for selected CNS agents. It organizes agents into Step 1 and Step 2 groups and requires documented trials of lower-step products before approving higher-step or brand products, subject to specified exceptions. For Auvelity (dextromethorphan/bupropion) the standard requirement is a trial of a generic SSRI or SNRI AND bupropion within the prior 180 days, but coverage may be granted without those prerequisites for current suicidal ideation, if requested for agitation associated with dementia due to Alzheimer’s disease, or if the member is currently taking or has previously taken Auvelity. For trazodone products, the policy distinguishes generic trazodone tablets (Step 1) from Raldesy oral solution (Step 2) and requires a documented tablet trial (≥ a 1-day supply in the prior 180 days) unless the member has difficulty swallowing tablets or is a current/prior Raldesy user.

    Definitions & Exceptions

    Step 1 trial — definition
    DefinitionStep 1 trial = trial of a listed Step 1 drug; considered met if patient had at least a 1-day supply within the prior 180 days where specified
    Examples (antidepressants)Bupropion SR/XL, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Venlafaxine IR/ER
    DocumentationProviders must document drug name and evidence of at least a 1-day supply within the prior 180 days to meet the trial requirement
    Exception — suicidal ideation (and related exceptions)
    ExceptionCurrent suicidal ideation permits approval without prerequisite trials for certain products (e.g., Exxua, Auvelity)
    Other exceptionsAgitation associated with dementia due to Alzheimer's disease allows Auvelity approval without prerequisite trials

    Initial Therapy — Step 1 Product Groups

    Initial therapy Step 1

    Initial Step 1 product groups

    Antidepressant Step 1 list: Generic antidepressants listed as Step 1 include bupropion SR/XL, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine IR/ER.N/A

    See policy product lists for specific strengths and formulations.

    Dextromethorphan/Bupropion Step 1 list: Step 1 for dextromethorphan/bupropion products includes generic SSRIs/SNRIs and bupropion formulations (see product list), which must be tried prior to Auvelity absent exceptions.N/A

    See policy product lists for specific agents and strengths.

    Trazodone Step 1 list:

    Continuation / Prior Use Criteria

    Continuation / Prior Use

    Continuation or ongoing therapy allowances

    Current or prior use allowance: Approve the requested product if the patient is currently taking it or has taken it in the past (applies to Exxua, Fanapt, Auvelity, and Raldesy as specified).documented current/prior use

    Documentation of current or prior use satisfies step requirement per respective sections.

    Step Therapy Tables — Required Trials by Product

    StepRequirementNotes / Exceptions
    Step 1One Step 1 drug trial with at least a 1-day supply within the prior 180 days is required before approving higher-step antidepressant products.Step 1 drugs include bupropion SR/XL, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine IR/ER. Exxua may be approved without prerequisite trials for patients with current suicidal ideation or if the patient is currently taking or has previously taken Exxua.
    StepRequirementNotes / Exceptions
    Step 2 (oral antipsychotic)Coverage requires two distinct Step 1 drug trials, each with at least a 1-day supply within the prior 180 days, before approving Step 2 oral antipsychotics (e.g., Fanapt).Step 1 drugs include listed oral formulations such as aripiprazole, asenapine, brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, xanomeline/trospium, or ziprasidone. Approve if patient is currently taking Fanapt or has taken Fanapt in the past.
    StepRequirementNotes / Exceptions
    Step 2 (Auvelity)Prior to approving Auvelity, the patient must have trialed a generic SSRI or SNRI AND bupropion for any trial duration within the previous 180 days.Exceptions: approve Auvelity without prerequisite trials for patients with current suicidal ideation, for agitation associated with Alzheimer's dementia, or if the patient is currently taking or has previously taken Auvelity. Follow antidepressant Step 1 drug list for eligible SSRI/SNRI and bupropion products.
    StepRequirementNotes / Exceptions
    Step 1 / Step 2Trazodone products are organized into Step 1 (generic trazodone tablets) and Step 2 (Raldesy oral solution).Step 1 lists trazodone 100 mg and 150 mg tablets; Step 2 is Raldesy 10 mg/mL oral solution. No additional trial logic provided beyond the tablet-to-Raldesy sequence in this section.
    StepRequirementNotes / Exceptions
    Step 1Patient must have trialed a tablet dosage form of generic trazodone (any listed tablet strength) with at least a 1-day supply in the prior 180 days to meet the Step 1 requirement.Tablet strengths referenced include 50 mg, 100 mg, and 150 mg. Documentation should show at least a 1-day supply within the prior 180 days. If the Step 1 tablet trial is met, proceed to consider Raldesy per Step 2 criteria.
    Step 2 (Raldesy)Approve Raldesy 10 mg/mL oral solution if the Step 1 tablet trial is met, or if the patient has difficulty swallowing tablets, is currently taking Raldesy, or has taken Raldesy at any time in the past.Documentation may include inability to swallow tablets, current use, or prior use of Raldesy as reasons to approve without an additional tablet trial beyond the requirements stated.
    Policy Summary
    Payermeridian
    Policy2026 Step Therapy Criteria — select CNS agents
    Policy CodePolicy N/A
    Change TypeMinor — no material coverage changes
    Effective DateAug 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain and document required prior Step drug trials (timing and products per section) or clearly document an approved exception when requesting prior authorization.
    SourceLink
    On This Page
    Coverage Criteria — Step Therapy RulesOperational Parameters & LookbackProvider Requirements, Prior Authorization & DocumentationBackground & Policy ScopeDefinitions & ExceptionsInitial Therapy — Step 1 Product GroupsContinuation / Prior Use CriteriaStep Therapy Tables — Required Trials by Product
    Exxua may be approved without prerequisite trials for current suicidal ideation or current/prior Exxua use; Auvelity has additional exceptions
    Minimum Step 1 trials — Oral antipsychotics
    Minimum Step 1 trials>= 2 distinct Step 1 drug trials
    Trial duration definitionEach trial = at least a 1-day supply within the prior 180 days
    Counting equivalentsA trial of the brand-name equivalent of a generic Step 1 product also counts toward the requirement
    Tablet trial window — Trazodone
    Tablet trial windowAt least a 1-day supply of a generic trazodone tablet within the prior 180 days
    Applies toStep 1 prerequisite for Raldesy (Step 2) approval
    Tablet strengths referencedGeneric trazodone tablets include 50 mg (and other strengths listed elsewhere: 100 mg, 150 mg)
    Step Therapy

    Document trials of listed Step 1 (and Step 2 where noted) products

    Providers must document trials of the listed Step 1 products (and Step 2 where applicable) described in each section before coverage of higher-step or brand products will be approved, subject to specified exceptions.

    • Step 1 antidepressant list includes bupropion SR/XL, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine IR/ER (one trial within prior 180 days).
    • Auvelity requires trial of a generic SSRI or SNRI AND bupropion within prior 180 days unless exception applies.
    • Oral antipsychotics require two distinct Step 1 trials within prior 180 days for Step 2 approval.
    Step Therapy

    Two-step sequence: generic trazodone tablets then Raldesy

    Trazodone uses a two-step sequence: Step 1 requires a trial of a generic trazodone tablet formulation (50 mg, 100 mg, or 150 mg); Step 2 is Raldesy oral solution and may be approved only after Step 1 is met or an exception is documented.

    • Step 1 tablet strengths referenced include 50 mg, 100 mg, 150 mg.
    • Step 2 is Raldesy 10 mg/mL oral solution and requires Step 1 evidence or bypass justification.
    Documentation Required

    Document drug name and ≥1-day supply within prior 180 days when required

    When documenting prior trials or exceptions for PA, include the drug name and evidence of at least a 1-day supply within the prior 180 days where required; also document current or prior use of the requested product when that is the basis for approval.

    • Record the specific drug product and dispensing or administration dates demonstrating ≥1-day supply in the prior 180 days.
    • If relying on continuation/prior-use exception, document that the patient is currently taking or previously took the requested product.
    Documentation Required

    Support must show tablet-form trazodone trial or documented exception for Raldesy

    For Raldesy-specific support, document a trial of a tablet dosage form of generic trazodone (≥1-day supply within the prior 180 days) OR document an allowed reason to bypass the tablet trial such as documented difficulty swallowing tablets, current use of Raldesy, or prior use of Raldesy.

    • Tablet trial is satisfied by evidence of at least a 1-day supply in the prior 180 days.
    • Acceptable alternative documentation: difficulty swallowing tablets, current Raldesy use, or prior Raldesy use.
    Denial Risk

    Coverage may be denied if required Step trial history within 180 days is not documented

    If the required number and type of prior Step drug trials within the prior 180 days are not documented (for example, one Step 1 trial for certain antidepressants or two distinct Step 1 trials for oral antipsychotics), coverage may be denied.

    • Denial risk applies when requisite trials within the prior 180 days are missing and no exception is documented.
    • Examples: one Step 1 trial missing for antidepressant prerequisites; two distinct Step 1 trials missing for antipsychotic prerequisites.
    Denial Risk

    Prior tablet trazodone trial (≥1-day in prior 180 days) or exception required for Raldesy

    Coverage for Raldesy requires documentation of a prior trial of a tablet dosage form of generic trazodone with at least a 1-day supply in the prior 180 days, or documentation of an exception (difficulty swallowing, current/prior Raldesy use). Absence of this tablet trial documentation may trigger denial.

    • Tablet trial defined as ≥1-day supply within prior 180 days.
    • Exceptions that permit approval without tablet trial: inability to swallow tablets, current or prior use of Raldesy.
    Prior/current useCurrent or prior use of the requested product (Exxua or Auvelity) also permits approval without Step 1 trials
    Tablet trial — definition (generic trazodone)
    DefinitionTablet trial = trial of a tablet dosage form of generic trazodone; met if at least a 1-day supply was used within the prior 180 days
    PurposeUsed to satisfy the Step 1 prerequisite before approving Raldesy (oral solution)
    Documentation examplesRecord of a dispensed trazodone tablet (≥1-day supply) within 180 days or provider note documenting trial
    Raldesy — product definition
    Product identityRaldesy 10 mg/mL oral solution (oral liquid formulation of trazodone)
    Step placementListed as Step 2 (requires Step 1 tablet trial or qualifying bypass criteria)
    Bypass conditionsApprove if patient has difficulty swallowing tablets or is currently/previously taking Raldesy
    Trazodone Step 1 agents include trazodone 100 mg and 150 mg tablets (and 50 mg where listed).
    N/A

    At least a 1-day supply within prior 180 days counts as a trial where specified.

    Initial therapy

    Initial step

    Step 1 initial agents: Trial of a generic trazodone tablet formulation (50 mg, 100 mg, or 150 mg).At least 1-day supply within prior 180 days where specified

    A tablet trial is defined as ≥1-day supply in the prior 180 days.